US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lexaria Bioscience Corp

11.28

+0.93008.99%

Post-market: 11.17-0.1100-0.98%16:10 EDT

Volume:359.55K

Turnover:4.06M

Market Cap:18.64M

PE:-2.19

High:12.20

Open:10.30

Low:10.30

Close:10.35

52wk High:23.25

52wk Low:4.21

Shares:1.65M

Float Shares:1.61M

Volume Ratio:3.00

T/O Rate:22.27%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.1429

EPS(LYR):-9.9189

ROE:-162.77%

ROA:-81.30%

PB:3.93

PE(LYR):-1.14

Loading ...

Overview Company News Filings

Lexaria receives Australian patent grant for hypertension treatment compositions

Lexaria says oral GLP-1 drugs expand market as sector sales forecasts climb to USD 139 billion by 2030

Lexaria announces dosing completion in 2026 Animal Study 2

Lexaria completes dosing in animal study testing oral retatrutide, amycretin formulations

Lexaria Bioscience to attend BIO International Convention

Lexaria Bioscience announces ethics approval for Human Pilot Study 7

Lexaria wins ethics board clearance for oral semaglutide human pilot study #7

Lexaria CEO says pharma partner extends material transfer agreement through end-2026

Lexar invests in IoT sensor-and-SaaS firm Munisense

Lexaria seeks ethics approval for five-week oral semaglutide study versus Wegovy tablets

Lexaria CEO discusses DehydraTECH, GLP-1 strategy in new investor video series interview

Lexaria extends PharmaCO transfer agreement through Dec. 31, 2026

Lexaria Bioscience extends material transfer agreement with pharma company

Lexaria signs CRO contracts for GLP-1 animal study #2

Lexaria sees oral GLP-1 pill market reaching $17 billion-$60 billion by mid-2030s

Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study

Lexaria signs CRO contracts for GLP-1 animal study execution and reporting

Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary

Lexaria FY26 Q2 net loss narrows 43.8% to US$ 3 million; revenue drops to US$ 20,000

Lexaria Bioscience Corp expected to post a loss of 9 cents a share - Earnings Preview

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/LEXX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LEXX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXX\",,,,,undefined,":{"symbol":"LEXX","market":"US","secType":"STK","nameCN":"Lexaria Bioscience Corp","latestPrice":11.28,"timestamp":1788206400000,"preClose":10.35,"halted":0,"volume":359549,"hourTrading":{"tag":"盘后","latestPrice":11.17,"preClose":11.28,"latestTime":"16:10 EDT","volume":72,"amount":804.24,"timestamp":1788207004975,"change":-0.11,"changeRate":-0.009752,"amplitude":0},"delay":0,"changeRate":0.08985507246376809,"floatShares":1614429,"shares":1652500,"eps":-5.142899,"marketStatus":"Post-Mkt","change":0.93,"latestTime":"08-31 16:18:38 EDT","open":10.3,"high":12.2,"low":10.3,"amount":4059354,"amplitude":0.183575,"askPrice":11.44,"askSize":200,"bidPrice":9.7,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.142899,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788220800000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":10.35,"preHourTrading":{"tag":"盘前","latestPrice":11.33,"preClose":10.35,"latestTime":"08:54 EDT","volume":2,"amount":22.5742,"timestamp":1788180858318,"change":0.98,"changeRate":0.094686,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":11.17,"preClose":11.28,"latestTime":"16:10 EDT","volume":72,"amount":804.24,"timestamp":1788207004975,"change":-0.11,"changeRate":-0.009752,"amplitude":0},"volumeRatio":2.995962},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LEXX\",,,,,undefined,":{"symbol":"LEXX","floatShares":1614429,"roa":"-81.30%","roe":"-162.77%","lyrEps":-9.9189,"volumeRatio":2.995962,"shares":1652500,"dividePrice":0,"high":12.2,"amplitude":0.183575,"preClose":10.35,"low":10.3,"week52Low":4.21,"pbRate":"3.93","psRate":"96.08","week52High":23.25,"institutionHeld":0,"latestPrice":11.28,"committee":-0.333333,"eps":-5.142899,"divideRate":0,"volume":359549,"delay":0,"ttmEps":-5.142899,"open":10.3,"prevYearClose":9.255,"prevWeekClose":10.35,"prevMonthClose":5.865,"prevQuarterClose":8.4,"fiveDayClose":10.54,"twentyDayClose":4.75,"sixtyDayClose":9.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LEXX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-03","symbol":"LEXX","defaultRemindTime":1785763800000,"type":"split","dateTimestamp":1785729600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2026-07-13","symbol":"LEXX","fiscalQuarterEnding":"2026/05","expectedEps":-0.06,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1783915200000,"reportTimeType":"post","actualEps":-0.08},{"market":"US","date":"2026-04-13","symbol":"LEXX","fiscalQuarterEnding":"2026/02","expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1776052800000,"reportTimeType":"","actualEps":-0.06},{"market":"US","date":"2026-01-13","symbol":"LEXX","fiscalQuarterEnding":"2025/11","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1768280400000,"reportTimeType":"","actualEps":-0.07},{"date":"2025-11-28","symbol":"LEXX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1764320400000,"name":null,"time":"Pre-MKt","dateTimestamp":1764306000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LEXX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LEXX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1720670400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LEXX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LEXX","date":"2026-08-28","current":-2.175816,"percent":0.430794,"low":-12.974484,"twenty":-6.655382,"median":-2.327216,"eighty":-1.656775,"high":-0.671866,"avg":-3.715581,"sd":2.923102,"marketCap":19301164},"quantilePoints":[{"date":"2021-09-03","current":-9.746108,"twenty":-20.982035,"median":-11.189873,"eighty":-6.542848,"marketCap":35812482},{"date":"2021-09-10","current":-9.544997,"twenty":-20.824181,"median":-11.135597,"eighty":-6.542848,"marketCap":35073494},{"date":"2021-09-17","current":-9.777048,"twenty":-20.724576,"median":-11.078307,"eighty":-6.542848,"marketCap":35926172},{"date":"2021-09-24","current":-10.612428,"twenty":-20.701837,"median":-11.034169,"eighty":-6.558291,"marketCap":38995814},{"date":"2021-10-01","current":-9.869868,"twenty":-20.531178,"median":-10.981495,"eighty":-6.611265,"marketCap":36267243},{"date":"2021-10-08","current":-10.179268,"twenty":-20.488995,"median":-10.949822,"eighty":-6.633734,"marketCap":37404148},{"date":"2021-10-15","current":-10.581488,"twenty":-20.488995,"median":-10.905881,"eighty":-6.655994,"marketCap":38882123},{"date":"2021-10-22","current":-10.194738,"twenty":-20.471658,"median":-10.86231,"eighty":-6.666084,"marketCap":37460993},{"date":"2021-10-29","current":-9.575937,"twenty":-20.436451,"median":-10.830411,"eighty":-6.668536,"marketCap":35187184},{"date":"2021-11-05","current":-9.715167,"twenty":-20.327206,"median":-10.804878,"eighty":-6.791676,"marketCap":35698791},{"date":"2021-11-12","current":-10.148328,"twenty":-20.143564,"median":-10.737922,"eighty":-6.827422,"marketCap":37290457},{"date":"2021-11-19","current":-8.616797,"twenty":-20.02632,"median":-10.690687,"eighty":-6.849445,"marketCap":31662781},{"date":"2021-11-26","current":-8.260987,"twenty":-20.0069,"median":-10.671553,"eighty":-6.863479,"marketCap":30355342},{"date":"2021-12-03","current":-6.840174,"twenty":-19.934586,"median":-10.612428,"eighty":-6.863479,"marketCap":27545422},{"date":"2021-12-10","current":-7.025044,"twenty":-19.741749,"median":-10.596796,"eighty":-6.863479,"marketCap":28289893},{"date":"2021-12-17","current":-6.531754,"twenty":-19.615799,"median":-10.578981,"eighty":-6.826164,"marketCap":26303411},{"date":"2021-12-23","current":-6.191866,"twenty":-19.51938,"median":-10.535078,"eighty":-6.679019,"marketCap":24934681},{"date":"2021-12-31","current":-5.955422,"twenty":-19.356074,"median":-10.473198,"eighty":-6.628639,"marketCap":23982521},{"date":"2022-01-07","current":-6.443087,"twenty":-19.236954,"median":-10.457728,"eighty":-6.542848,"marketCap":25946351},{"date":"2022-01-14","current":-5.152781,"twenty":-19.117133,"median":-10.426788,"eighty":-6.542848,"marketCap":27434100},{"date":"2022-01-21","current":-5.052184,"twenty":-18.967952,"median":-10.401429,"eighty":-6.525243,"marketCap":26898510},{"date":"2022-01-28","current":-4.560379,"twenty":-18.668908,"median":-10.364908,"eighty":-6.502913,"marketCap":24280071},{"date":"2022-02-04","current":-4.392718,"twenty":-18.668908,"median":-10.347469,"eighty":-6.489782,"marketCap":23387422},{"date":"2022-02-11","current":-4.007097,"twenty":-18.667483,"median":-10.341251,"eighty":-6.469175,"marketCap":21334327},{"date":"2022-02-18","current":-4.314476,"twenty":-18.617444,"median":-10.333079,"eighty":-6.440892,"marketCap":22970852},{"date":"2022-02-25","current":-3.889735,"twenty":-18.440095,"median":-10.297161,"eighty":-6.416353,"marketCap":20709473},{"date":"2022-03-04","current":-3.710896,"twenty":-18.35776,"median":-10.259288,"eighty":-6.37702,"marketCap":19757313},{"date":"2022-03-11","current":-3.744429,"twenty":-18.272902,"median":-10.22525,"eighty":-6.357467,"marketCap":19935843},{"date":"2022-03-18","current":-3.107317,"twenty":-18.171071,"median":-10.224763,"eighty":-6.324865,"marketCap":16543774},{"date":"2022-03-25","current":-3.845025,"twenty":-17.891037,"median":-10.197982,"eighty":-6.318961,"marketCap":20471433},{"date":"2022-04-01","current":-3.688542,"twenty":-17.881648,"median":-10.179268,"eighty":-6.279787,"marketCap":19638293},{"date":"2022-04-08","current":-3.39234,"twenty":-17.785381,"median":-10.153858,"eighty":-6.221421,"marketCap":18061278},{"date":"2022-04-14","current":-3.185945,"twenty":-17.768281,"median":-10.122944,"eighty":-6.204693,"marketCap":22792322},{"date":"2022-04-22","current":-2.495518,"twenty":-17.575778,"median":-10.086448,"eighty":-6.185731,"marketCap":17852994},{"date":"2022-04-29","current":-2.312514,"twenty":-17.497699,"median":-10.042063,"eighty":-6.147983,"marketCap":16543774},{"date":"2022-05-06","current":-2.370742,"twenty":-17.489943,"median":-9.984656,"eighty":-6.122035,"marketCap":16960344},{"date":"2022-05-13","current":-1.705271,"twenty":-17.39456,"median":-9.962688,"eighty":-6.105634,"marketCap":12199545},{"date":"2022-05-20","current":-1.671997,"twenty":-17.285936,"median":-9.940712,"eighty":-6.09087,"marketCap":11961505},{"date":"2022-05-27","current":-1.713589,"twenty":-17.264742,"median":-9.93387,"eighty":-6.058044,"marketCap":12259055},{"date":"2022-06-03","current":-1.81341,"twenty":-17.257904,"median":-9.920751,"eighty":-6.023867,"marketCap":12973175},{"date":"2022-06-10","current":-1.988096,"twenty":-17.136229,"median":-9.900808,"eighty":-6.017376,"marketCap":14222885},{"date":"2022-06-17","current":-1.938186,"twenty":-17.051331,"median":-9.885602,"eighty":-5.98861,"marketCap":13865825},{"date":"2022-06-24","current":-2.736752,"twenty":-17.004275,"median":-9.878747,"eighty":-5.959552,"marketCap":19578783},{"date":"2022-07-01","current":-2.295877,"twenty":-16.835329,"median":-9.865791,"eighty":-5.937004,"marketCap":16424754},{"date":"2022-07-08","current":-2.428971,"twenty":-16.675346,"median":-9.823458,"eighty":-5.903478,"marketCap":17376914},{"date":"2022-07-15","current":-2.438392,"twenty":-16.66574,"median":-9.800253,"eighty":-5.868301,"marketCap":17019854},{"date":"2022-07-22","current":-2.387237,"twenty":-16.651735,"median":-9.761578,"eighty":-5.823139,"marketCap":16662794},{"date":"2022-07-29","current":-2.301978,"twenty":-16.589073,"median":-9.747431,"eighty":-5.807068,"marketCap":16067694},{"date":"2022-08-05","current":-2.408551,"twenty":-16.505285,"median":-9.746108,"eighty":-5.766272,"marketCap":16811569},{"date":"2022-08-12","current":-2.796477,"twenty":-16.452472,"median":-9.699697,"eighty":-5.752153,"marketCap":19519273},{"date":"2022-08-19","current":-2.361659,"twenty":-16.36772,"median":-9.668758,"eighty":-5.723569,"marketCap":16484264},{"date":"2022-08-26","current":-2.472495,"twenty":-16.30819,"median":-9.653288,"eighty":-5.719391,"marketCap":17257894},{"date":"2022-09-02","current":-2.544965,"twenty":-16.294271,"median":-9.637817,"eighty":-5.698952,"marketCap":17763729},{"date":"2022-09-09","current":-2.702693,"twenty":-16.238593,"median":-9.622347,"eighty":-5.63867,"marketCap":18864663},{"date":"2022-09-16","current":-2.417077,"twenty":-16.234654,"median":-9.606878,"eighty":-5.600553,"marketCap":16871079},{"date":"2022-09-23","current":-2.105884,"twenty":-16.195923,"median":-9.584217,"eighty":-5.561251,"marketCap":14698965},{"date":"2022-09-30","current":-2.088832,"twenty":-16.194972,"median":-9.568073,"eighty":-5.554352,"marketCap":14579945},{"date":"2022-10-07","current":-1.884212,"twenty":-16.117012,"median":-9.560467,"eighty":-5.500415,"marketCap":13151705},{"date":"2022-10-14","current":-1.798953,"twenty":-16.06593,"median":-9.544081,"eighty":-5.437212,"marketCap":12556605},{"date":"2022-10-21","current":-1.756324,"twenty":-16.055261,"median":-9.518871,"eighty":-5.376914,"marketCap":12259055},{"date":"2022-10-28","current":-1.901263,"twenty":-16.055261,"median":-9.506322,"eighty":-5.316693,"marketCap":13270725},{"date":"2022-11-04","current":-1.853092,"twenty":-16.018697,"median":-9.483058,"eighty":-5.249722,"marketCap":12934494},{"date":"2022-11-11","current":-2.012099,"twenty":-15.999369,"median":-9.465212,"eighty":-5.161838,"marketCap":14044355},{"date":"2022-11-18","current":-1.875686,"twenty":-15.953664,"median":-9.433393,"eighty":-5.052184,"marketCap":13092195},{"date":"2022-11-25","current":-2.020625,"twenty":-15.921079,"median":-9.421237,"eighty":-4.916007,"marketCap":14103865},{"date":"2022-12-02","current":-2.414922,"twenty":-15.800117,"median":-9.406458,"eighty":-4.808471,"marketCap":17554849},{"date":"2022-12-09","current":-2.398631,"twenty":-15.771913,"median":-9.374504,"eighty":-4.781462,"marketCap":17436424},{"date":"2022-12-16","current":-2.193969,"twenty":-15.76565,"median":-9.351067,"eighty":-4.644331,"marketCap":15948674},{"date":"2022-12-23","current":-2.005681,"twenty":-15.66997,"median":-9.282007,"eighty":-4.550807,"marketCap":14579945},{"date":"2022-12-30","current":-2.013867,"twenty":-15.646442,"median":-9.280758,"eighty":-4.497998,"marketCap":14639455},{"date":"2023-01-06","current":-2.202156,"twenty":-15.566057,"median":-9.2003,"eighty":-4.46149,"marketCap":16008184},{"date":"2023-01-13","current":-2.267647,"twenty":-15.371731,"median":-9.154215,"eighty":-4.348865,"marketCap":16484264},{"date":"2023-01-20","current":-2.301829,"twenty":-15.296539,"median":-9.072941,"eighty":-4.332713,"marketCap":16186714},{"date":"2023-01-27","current":-2.488006,"twenty":-15.134452,"median":-8.999523,"eighty":-4.281096,"marketCap":17495934},{"date":"2023-02-03","current":-2.547244,"twenty":-15.061324,"median":-8.939785,"eighty":-4.234421,"marketCap":17912503},{"date":"2023-02-10","current":-2.377992,"twenty":-14.980795,"median":-8.912362,"eighty":-4.200782,"marketCap":16722304},{"date":"2023-02-17","current":-2.572378,"twenty":-14.909476,"median":-8.88494,"eighty":-4.07975,"marketCap":18089248},{"date":"2023-02-24","current":-2.538782,"twenty":-14.844896,"median":-8.819202,"eighty":-4.017157,"marketCap":17852994},{"date":"2023-03-03","current":-2.648795,"twenty":-14.786699,"median":-8.718288,"eighty":-3.831612,"marketCap":18626623},{"date":"2023-03-10","current":-2.488006,"twenty":-14.7336,"median":-8.624543,"eighty":-3.777961,"marketCap":17495934},{"date":"2023-03-17","current":-2.157964,"twenty":-14.643442,"median":-8.603064,"eighty":-3.688542,"marketCap":15175044},{"date":"2023-03-24","current":-2.127971,"twenty":-14.519701,"median":-8.554917,"eighty":-3.567825,"marketCap":14964125},{"date":"2023-03-31","current":-2.315232,"twenty":-14.463957,"median":-8.486299,"eighty":-3.391222,"marketCap":16280968},{"date":"2023-04-06","current":-1.979013,"twenty":-14.378658,"median":-8.403234,"eighty":-3.335336,"marketCap":13916636},{"date":"2023-04-14","current":-1.966245,"twenty":-14.287498,"median":-8.311435,"eighty":-3.154494,"marketCap":13826851},{"date":"2023-04-21","current":-1.907234,"twenty":-14.209652,"median":-8.249563,"eighty":-2.791565,"marketCap":13168430},{"date":"2023-04-28","current":-1.892843,"twenty":-14.052638,"median":-8.158239,"eighty":-2.73978,"marketCap":13069068},{"date":"2023-05-05","current":-1.187686,"twenty":-13.914167,"median":-8.083856,"eighty":-2.69968,"marketCap":8200340},{"date":"2023-05-12","current":-0.679495,"twenty":-13.712693,"median":-7.963612,"eighty":-2.682794,"marketCap":4691552},{"date":"2023-05-19","current":-1.035296,"twenty":-13.580704,"median":-7.870301,"eighty":-2.589574,"marketCap":7148163},{"date":"2023-05-26","current":-0.878958,"twenty":-13.460618,"median":-7.865587,"eighty":-2.570177,"marketCap":6068737},{"date":"2023-06-02","current":-0.890678,"twenty":-13.412897,"median":-7.788843,"eighty":-2.562883,"marketCap":6149654},{"date":"2023-06-07","current":-0.891264,"twenty":-13.379485,"median":-7.750301,"eighty":-2.551939,"marketCap":6153699},{"date":"2023-06-15","current":-0.846378,"twenty":-13.234305,"median":-7.6805,"eighty":-2.544965,"marketCap":5843789},{"date":"2023-06-23","current":-0.978573,"twenty":-13.163346,"median":-7.611749,"eighty":-2.520854,"marketCap":6756527},{"date":"2023-06-30","current":-0.870169,"twenty":-13.029994,"median":-7.521467,"eighty":-2.513394,"marketCap":6008050},{"date":"2023-07-07","current":-0.902397,"twenty":-12.943419,"median":-7.472673,"eighty":-2.504275,"marketCap":6230570},{"date":"2023-07-14","current":-0.972714,"twenty":-12.889745,"median":-7.435218,"eighty":-2.488006,"marketCap":6716069},{"date":"2023-07-21","current":-0.892153,"twenty":-12.803082,"median":-7.349407,"eighty":-2.465674,"marketCap":6149654},{"date":"2023-07-28","current":-0.933239,"twenty":-12.729177,"median":-7.31323,"eighty":-2.440772,"marketCap":6432861},{"date":"2023-08-04","current":-0.987238,"twenty":-12.617531,"median":-7.225926,"eighty":-2.428809,"marketCap":6805077},{"date":"2023-08-11","current":-1.197364,"twenty":-12.500813,"median":-7.101059,"eighty":-2.42134,"marketCap":8253483},{"date":"2023-08-18","current":-1.220842,"twenty":-12.383388,"median":-7.064426,"eighty":-2.41243,"marketCap":8415316},{"date":"2023-08-25","current":-1.279536,"twenty":-12.336572,"median":-6.955491,"eighty":-2.398735,"marketCap":8819898},{"date":"2023-09-01","current":-1.232463,"twenty":-12.11462,"median":-6.875913,"eighty":-2.387237,"marketCap":8495423},{"date":"2023-09-08","current":-1.013064,"twenty":-12.086798,"median":-6.828681,"eighty":-2.377992,"marketCap":6983093},{"date":"2023-09-15","current":-1.115428,"twenty":-11.968099,"median":-6.668826,"eighty":-2.370742,"marketCap":7688693},{"date":"2023-09-22","current":-1.079975,"twenty":-11.813295,"median":-6.618092,"eighty":-2.362271,"marketCap":7444318},{"date":"2023-09-29","current":-1.138669,"twenty":-11.717442,"median":-6.542848,"eighty":-2.353044,"marketCap":7848900},{"date":"2023-10-06","current":-1.198664,"twenty":-11.638981,"median":-6.520681,"eighty":-2.340161,"marketCap":8262448},{"date":"2023-10-13","current":-1.276707,"twenty":-11.526163,"median":-6.499819,"eighty":-2.320472,"marketCap":8800396},{"date":"2023-10-20","current":-1.407128,"twenty":-11.488271,"median":-6.473736,"eighty":-2.310478,"marketCap":9699395},{"date":"2023-10-27","current":-1.459244,"twenty":-11.407561,"median":-6.454631,"eighty":-2.307051,"marketCap":10058632},{"date":"2023-11-03","current":-1.863141,"twenty":-11.200524,"median":-6.416353,"eighty":-2.296343,"marketCap":12842718},{"date":"2023-11-10","current":-2.221231,"twenty":-11.072124,"median":-6.374521,"eighty":-2.286817,"marketCap":15311046},{"date":"2023-11-17","current":-1.966568,"twenty":-10.97961,"median":-6.351632,"eighty":-2.246358,"marketCap":13555640},{"date":"2023-11-24","current":-2.019895,"twenty":-10.923124,"median":-6.324753,"eighty":-2.211171,"marketCap":13462399},{"date":"2023-12-01","current":-2.312857,"twenty":-10.83906,"median":-6.280532,"eighty":-2.210358,"marketCap":15414961},{"date":"2023-12-08","current":-2.220343,"twenty":-10.797412,"median":-6.231466,"eighty":-2.210358,"marketCap":14798363},{"date":"2023-12-15","current":-2.143248,"twenty":-10.687142,"median":-6.201269,"eighty":-2.187213,"marketCap":14284530},{"date":"2023-12-22","current":-2.066153,"twenty":-10.612428,"median":-6.179172,"eighty":-2.171698,"marketCap":13770698},{"date":"2023-12-29","current":-1.973638,"twenty":-10.596958,"median":-6.140861,"eighty":-2.157964,"marketCap":13154100},{"date":"2024-01-05","current":-2.143248,"twenty":-10.573585,"median":-6.117977,"eighty":-2.139346,"marketCap":14284530},{"date":"2024-01-12","current":-2.343696,"twenty":-10.462732,"median":-6.097421,"eighty":-2.131306,"marketCap":15620494},{"date":"2024-01-19","current":-2.742435,"twenty":-10.414921,"median":-6.060406,"eighty":-2.131152,"marketCap":16696705},{"date":"2024-01-26","current":-2.530945,"twenty":-10.363099,"median":-6.025016,"eighty":-2.131306,"marketCap":15409096},{"date":"2024-02-02","current":-2.721633,"twenty":-10.341251,"median":-6.014533,"eighty":-2.131306,"marketCap":16570056},{"date":"2024-02-09","current":-3.293696,"twenty":-10.266818,"median":-5.973923,"eighty":-2.131306,"marketCap":20052934},{"date":"2024-02-16","current":-4.091117,"twenty":-10.224822,"median":-5.937004,"eighty":-2.131306,"marketCap":24907855},{"date":"2024-02-23","current":-5.054829,"twenty":-10.196036,"median":-5.895319,"eighty":-2.131306,"marketCap":30775207},{"date":"2024-03-01","current":-7.68245,"twenty":-10.148328,"median":-5.877884,"eighty":-2.131461,"marketCap":46772892},{"date":"2024-03-08","current":-10.165167,"twenty":-10.086448,"median":-5.877884,"eighty":-2.131461,"marketCap":61888365},{"date":"2024-03-15","current":-7.827179,"twenty":-10.040038,"median":-5.877884,"eighty":-2.131461,"marketCap":47654041},{"date":"2024-03-22","current":-6.993635,"twenty":-9.962688,"median":-5.877884,"eighty":-2.131461,"marketCap":42579195},{"date":"2024-03-28","current":-7.542554,"twenty":-9.935991,"median":-5.877884,"eighty":-2.131461,"marketCap":45921166},{"date":"2024-04-05","current":-6.63909,"twenty":-9.90079,"median":-5.861912,"eighty":-2.131306,"marketCap":40420623},{"date":"2024-04-12","current":-5.945755,"twenty":-9.870325,"median":-5.861912,"eighty":-2.131306,"marketCap":32343039},{"date":"2024-04-19","current":-5.32986,"twenty":-9.807988,"median":-5.814067,"eighty":-2.131306,"marketCap":28992764},{"date":"2024-04-26","current":-5.18773,"twenty":-9.748753,"median":-5.782168,"eighty":-2.131461,"marketCap":28219623},{"date":"2024-05-03","current":-7.10648,"twenty":-9.715167,"median":-5.779641,"eighty":-2.131461,"marketCap":38657019},{"date":"2024-05-10","current":-8.527776,"twenty":-9.653288,"median":-5.779641,"eighty":-2.131461,"marketCap":46388422},{"date":"2024-05-17","current":-7.438116,"twenty":-9.622347,"median":-5.779641,"eighty":-2.131461,"marketCap":40461013},{"date":"2024-05-24","current":-6.822221,"twenty":-9.584217,"median":-5.779641,"eighty":-2.131461,"marketCap":37110738},{"date":"2024-05-31","current":-9.451618,"twenty":-9.560467,"median":-5.779641,"eighty":-2.131461,"marketCap":51413835},{"date":"2024-06-07","current":-8.077699,"twenty":-9.529527,"median":-5.779641,"eighty":-2.131461,"marketCap":43940144},{"date":"2024-06-14","current":-8.66286,"twenty":-9.498587,"median":-5.777581,"eighty":-2.131306,"marketCap":47123239},{"date":"2024-06-21","current":-7.583294,"twenty":-9.463548,"median":-5.770513,"eighty":-2.131152,"marketCap":41250738},{"date":"2024-06-28","current":-6.925022,"twenty":-9.421237,"median":-5.76339,"eighty":-2.130688,"marketCap":37669944},{"date":"2024-07-05","current":-6.951353,"twenty":-9.404254,"median":-5.76339,"eighty":-2.130688,"marketCap":37813176},{"date":"2024-07-12","current":-7.398978,"twenty":-9.312947,"median":-5.76339,"eighty":-2.130688,"marketCap":40248116},{"date":"2024-07-15","current":-9.095179,"twenty":-9.282007,"median":-5.76339,"eighty":-2.130688,"marketCap":44110471},{"date":"2024-08-02","current":-12.974484,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":62924615},{"date":"2024-08-09","current":-10.790338,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":52331778},{"date":"2024-08-16","current":-10.26875,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":49802145},{"date":"2024-08-23","current":-9.87756,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":47904921},{"date":"2024-08-30","current":-10.529544,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":51066962},{"date":"2024-09-06","current":-10.757738,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":52173676},{"date":"2024-09-13","current":-11.474921,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":55651921},{"date":"2024-09-20","current":-10.26875,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":49802145},{"date":"2024-09-27","current":-9.681965,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":46956308},{"date":"2024-10-04","current":-10.790338,"twenty":-9.20682,"median":-5.725627,"eighty":-2.124643,"marketCap":52331778},{"date":"2024-10-11","current":-9.975358,"twenty":-9.214735,"median":-5.725627,"eighty":-2.124643,"marketCap":48379227},{"date":"2024-10-18","current":-9.225576,"twenty":-9.216122,"median":-5.725627,"eighty":-2.124643,"marketCap":44742880},{"date":"2024-10-25","current":-9.824086,"twenty":-9.213308,"median":-5.725627,"eighty":-2.124643,"marketCap":47645581},{"date":"2024-10-31","current":-8.168746,"twenty":-9.187013,"median":-5.725627,"eighty":-2.124643,"marketCap":39617388},{"date":"2024-11-08","current":-8.348674,"twenty":-9.105428,"median":-5.722197,"eighty":-2.123533,"marketCap":40490018},{"date":"2024-11-15","current":-7.628961,"twenty":-9.066105,"median":-5.722197,"eighty":-2.123533,"marketCap":36999499},{"date":"2024-11-22","current":-7.772904,"twenty":-9.020491,"median":-5.722197,"eighty":-2.123533,"marketCap":37697603},{"date":"2024-11-29","current":-6.263889,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":36301395},{"date":"2024-12-06","current":-7.046875,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":40839069},{"date":"2024-12-13","current":-6.805956,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":39442862},{"date":"2024-12-20","current":-6.655382,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":38570232},{"date":"2024-12-27","current":-7.137219,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":41362647},{"date":"2025-01-03","current":-6.926415,"twenty":-9.001137,"median":-5.722197,"eighty":-2.123533,"marketCap":40140966},{"date":"2025-01-10","current":-6.655382,"twenty":-9.001541,"median":-5.722194,"eighty":-2.122424,"marketCap":38570232},{"date":"2025-01-17","current":-4.736024,"twenty":-8.999523,"median":-5.708343,"eighty":-2.122424,"marketCap":34666373},{"date":"2025-01-24","current":-4.364336,"twenty":-8.988077,"median":-5.687855,"eighty":-2.122424,"marketCap":31945721},{"date":"2025-01-31","current":-4.364336,"twenty":-8.953496,"median":-5.614061,"eighty":-2.122424,"marketCap":31945721},{"date":"2025-02-07","current":-4.532195,"twenty":-8.939785,"median":-5.573822,"eighty":-2.122424,"marketCap":33174402},{"date":"2025-02-14","current":-3.66892,"twenty":-8.895257,"median":-5.554362,"eighty":-2.122424,"marketCap":26855468},{"date":"2025-02-21","current":-3.429121,"twenty":-8.720404,"median":-5.505891,"eighty":-2.122424,"marketCap":25100209},{"date":"2025-02-28","current":-3.716879,"twenty":-8.66286,"median":-5.444257,"eighty":-2.122424,"marketCap":27206520},{"date":"2025-03-07","current":-3.309222,"twenty":-8.674369,"median":-5.376914,"eighty":-2.120821,"marketCap":24222579},{"date":"2025-03-14","current":-3.165343,"twenty":-8.674369,"median":-5.344313,"eighty":-2.120821,"marketCap":23169424},{"date":"2025-03-21","current":-3.788819,"twenty":-8.674369,"median":-5.316693,"eighty":-2.120821,"marketCap":27733098},{"date":"2025-03-28","current":-4.196477,"twenty":-8.674369,"median":-5.211418,"eighty":-2.120821,"marketCap":30717039},{"date":"2025-04-04","current":-3.66892,"twenty":-8.674369,"median":-5.166169,"eighty":-2.120821,"marketCap":26855468},{"date":"2025-04-11","current":-3.213302,"twenty":-8.66286,"median":-5.148914,"eighty":-2.122424,"marketCap":23520475},{"date":"2025-04-17","current":-2.619825,"twenty":-8.66286,"median":-5.027237,"eighty":-2.122424,"marketCap":24582850},{"date":"2025-04-25","current":-3.162503,"twenty":-8.674369,"median":-4.921084,"eighty":-2.120821,"marketCap":29675012},{"date":"2025-05-02","current":-2.301703,"twenty":-8.674369,"median":-4.808929,"eighty":-2.120821,"marketCap":21597790},{"date":"2025-05-09","current":-2.20104,"twenty":-8.674369,"median":-4.772307,"eighty":-2.120821,"marketCap":20653229},{"date":"2025-05-16","current":-2.138747,"twenty":-8.674369,"median":-4.713965,"eighty":-2.120821,"marketCap":20068704},{"date":"2025-05-23","current":-2.01416,"twenty":-8.674369,"median":-4.577753,"eighty":-2.103843,"marketCap":18899653},{"date":"2025-05-30","current":-2.149129,"twenty":-8.674369,"median":-4.556175,"eighty":-2.103843,"marketCap":20166125},{"date":"2025-06-06","current":-2.055896,"twenty":-8.674369,"median":-4.507162,"eighty":-2.088575,"marketCap":19291285},{"date":"2025-06-13","current":-2.117982,"twenty":-8.674369,"median":-4.460255,"eighty":-2.081572,"marketCap":19873862},{"date":"2025-06-20","current":-2.076453,"twenty":-8.685878,"median":-4.364336,"eighty":-2.076453,"marketCap":19484179},{"date":"2025-06-27","current":-1.784919,"twenty":-8.685878,"median":-4.348437,"eighty":-2.064664,"marketCap":16748600},{"date":"2025-07-03","current":-1.868808,"twenty":-8.685878,"median":-4.331537,"eighty":-2.055429,"marketCap":17535761},{"date":"2025-07-11","current":-1.868808,"twenty":-8.685878,"median":-4.302415,"eighty":-2.032165,"marketCap":17535761},{"date":"2025-07-18","current":-1.493881,"twenty":-8.685878,"median":-4.248124,"eighty":-2.018863,"marketCap":17016485},{"date":"2025-07-25","current":-1.734275,"twenty":-8.685878,"median":-4.239429,"eighty":-2.013867,"marketCap":19754770},{"date":"2025-08-01","current":-1.545394,"twenty":-8.649381,"median":-4.227439,"eighty":-2.007155,"marketCap":17603261},{"date":"2025-08-08","current":-1.425196,"twenty":-8.629173,"median":-4.182011,"eighty":-2.002261,"marketCap":16234118},{"date":"2025-08-15","current":-1.371966,"twenty":-8.629173,"median":-4.111394,"eighty":-1.993395,"marketCap":15627784},{"date":"2025-08-22","current":-1.349472,"twenty":-8.629173,"median":-4.083847,"eighty":-1.980278,"marketCap":15371558},{"date":"2025-08-29","current":-1.528223,"twenty":-8.629173,"median":-4.01548,"eighty":-1.970664,"marketCap":17407669},{"date":"2025-09-05","current":-1.657692,"twenty":-8.635361,"median":-3.967976,"eighty":-1.962047,"marketCap":18882431},{"date":"2025-09-12","current":-1.837301,"twenty":-8.629173,"median":-3.852892,"eighty":-1.951696,"marketCap":20928321},{"date":"2025-09-19","current":-2.094867,"twenty":-8.629173,"median":-3.800316,"eighty":-1.951696,"marketCap":23862198},{"date":"2025-09-26","current":-2.627169,"twenty":-8.629173,"median":-3.761195,"eighty":-1.951696,"marketCap":29925543},{"date":"2025-10-03","current":-1.527364,"twenty":-8.629173,"median":-3.688542,"eighty":-1.926272,"marketCap":17397889},{"date":"2025-10-10","current":-1.740679,"twenty":-8.629173,"median":-3.66892,"eighty":-1.912482,"marketCap":19827709},{"date":"2025-10-17","current":-1.610445,"twenty":-8.629173,"median":-3.607841,"eighty":-1.897885,"marketCap":18344245},{"date":"2025-10-24","current":-1.7768,"twenty":-8.629173,"median":-3.513775,"eighty":-1.888909,"marketCap":20239165},{"date":"2025-10-31","current":-1.920311,"twenty":-8.629173,"median":-3.453101,"eighty":-1.883018,"marketCap":21873867},{"date":"2025-11-07","current":-2.10873,"twenty":-8.629173,"median":-3.39874,"eighty":-1.883018,"marketCap":24020108},{"date":"2025-11-14","current":-2.147781,"twenty":-8.629173,"median":-3.373109,"eighty":-1.883018,"marketCap":24464925},{"date":"2025-11-21","current":-2.157543,"twenty":-8.629173,"median":-3.34321,"eighty":-1.883018,"marketCap":24576129},{"date":"2025-11-28","current":-2.035498,"twenty":-8.629173,"median":-3.278748,"eighty":-1.883018,"marketCap":24226172},{"date":"2025-12-05","current":-2.091521,"twenty":-8.629173,"median":-3.228187,"eighty":-1.883018,"marketCap":24892947},{"date":"2025-12-12","current":-2.296938,"twenty":-8.629173,"median":-3.175644,"eighty":-1.883018,"marketCap":27337790},{"date":"2025-12-19","current":-1.279376,"twenty":-8.629173,"median":-2.995852,"eighty":-1.874558,"marketCap":15226927},{"date":"2025-12-26","current":-1.170993,"twenty":-8.629173,"median":-2.889864,"eighty":-1.868808,"marketCap":13936969},{"date":"2026-01-02","current":-1.290183,"twenty":-8.629173,"median":-2.789026,"eighty":-1.863248,"marketCap":15355554},{"date":"2026-01-09","current":-1.453286,"twenty":-8.629173,"median":-2.742117,"eighty":-1.853183,"marketCap":17296774},{"date":"2026-01-16","current":-1.68535,"twenty":-8.629173,"median":-2.724952,"eighty":-1.842693,"marketCap":18190234},{"date":"2026-01-23","current":-1.884115,"twenty":-8.629173,"median":-2.698926,"eighty":-1.839412,"marketCap":20335532},{"date":"2026-01-30","current":-1.742996,"twenty":-8.629173,"median":-2.682082,"eighty":-1.830746,"marketCap":18812420},{"date":"2026-02-06","current":-1.526477,"twenty":-8.555297,"median":-2.647022,"eighty":-1.815946,"marketCap":16475489},{"date":"2026-02-13","current":-1.430322,"twenty":-8.508439,"median":-2.603213,"eighty":-1.809963,"marketCap":15437682},{"date":"2026-02-20","current":-1.521404,"twenty":-8.395121,"median":-2.588823,"eighty":-1.802959,"marketCap":16420736},{"date":"2026-02-27","current":-1.656757,"twenty":-8.348674,"median":-2.581747,"eighty":-1.796773,"marketCap":17881629},{"date":"2026-03-06","current":-1.784502,"twenty":-8.342472,"median":-2.565947,"eighty":-1.78544,"marketCap":19260394},{"date":"2026-03-13","current":-1.565215,"twenty":-8.29406,"median":-2.551487,"eighty":-1.77395,"marketCap":16893598},{"date":"2026-03-20","current":-1.671745,"twenty":-8.214858,"median":-2.537946,"eighty":-1.764931,"marketCap":18043398},{"date":"2026-03-27","current":-1.730314,"twenty":-8.214858,"median":-2.521631,"eighty":-1.763043,"marketCap":18675539},{"date":"2026-04-02","current":-1.997102,"twenty":-8.214858,"median":-2.513478,"eighty":-1.762415,"marketCap":21555016},{"date":"2026-04-10","current":-2.086569,"twenty":-8.214858,"median":-2.505764,"eighty":-1.762415,"marketCap":22520649},{"date":"2026-04-17","current":-2.561999,"twenty":-8.134153,"median":-2.504931,"eighty":-1.762415,"marketCap":24415634},{"date":"2026-04-24","current":-2.452496,"twenty":-8.10452,"median":-2.503096,"eighty":-1.762415,"marketCap":23372082},{"date":"2026-05-01","current":-1.714068,"twenty":-8.027011,"median":-2.485552,"eighty":-1.759534,"marketCap":16334926},{"date":"2026-05-08","current":-1.66647,"twenty":-7.848651,"median":-2.470314,"eighty":-1.756324,"marketCap":15881316},{"date":"2026-05-15","current":-1.588959,"twenty":-7.759342,"median":-2.45822,"eighty":-1.742069,"marketCap":15142650},{"date":"2026-05-22","current":-1.575174,"twenty":-7.709097,"median":-2.444908,"eighty":-1.731837,"marketCap":15011277},{"date":"2026-05-29","current":-1.612889,"twenty":-7.599093,"median":-2.438288,"eighty":-1.717202,"marketCap":15370695},{"date":"2026-06-05","current":-1.654245,"twenty":-7.534517,"median":-2.42319,"eighty":-1.706014,"marketCap":15764815},{"date":"2026-06-12","current":-1.66699,"twenty":-7.464476,"median":-2.418691,"eighty":-1.70523,"marketCap":15886274},{"date":"2026-06-18","current":-1.587919,"twenty":-7.394035,"median":-2.412334,"eighty":-1.691263,"marketCap":15132735},{"date":"2026-06-26","current":-1.422755,"twenty":-7.284521,"median":-2.398631,"eighty":-1.682583,"marketCap":13558732},{"date":"2026-07-02","current":-1.48778,"twenty":-7.228603,"median":-2.387237,"eighty":-1.679723,"marketCap":14178419},{"date":"2026-07-10","current":-1.599624,"twenty":-7.114809,"median":-2.377992,"eighty":-1.671997,"marketCap":15244279},{"date":"2026-07-17","current":-1.793333,"twenty":-7.071007,"median":-2.370742,"eighty":-1.671846,"marketCap":13866097},{"date":"2026-07-24","current":-1.827956,"twenty":-6.995415,"median":-2.362424,"eighty":-1.671846,"marketCap":14133801},{"date":"2026-07-31","current":-1.270464,"twenty":-6.923412,"median":-2.357057,"eighty":-1.671745,"marketCap":9823264},{"date":"2026-08-07","current":-1.14127,"twenty":-6.865357,"median":-2.346604,"eighty":-1.66315,"marketCap":8824333},{"date":"2026-08-14","current":-1.731141,"twenty":-6.783839,"median":-2.332415,"eighty":-1.656775,"marketCap":13385225},{"date":"2026-08-21","current":-2.408637,"twenty":-6.714926,"median":-2.327746,"eighty":-1.656775,"marketCap":18623641},{"date":"2026-08-28","current":-2.496262,"twenty":-6.655382,"median":-2.327216,"eighty":-1.656775,"marketCap":19301164}],"updateTime":1788185071071},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LEXX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2645199831","title":"Lexaria receives Australian patent grant for hypertension treatment compositions","url":"https://stock-news.laohu8.com/highlight/detail?id=2645199831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645199831?lang=en_us&edition=fundamental","pubTime":"2026-06-23 21:25","pubTimestamp":1782221130,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience received an Australian patent grant, No. 2023302884, covering pharmaceutical compositions and methods for treating hypertension.The grant marks the company’s seventh issued patent in the same family, with prior grants in the U.S., Europe, and Japan.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL2HxbmB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644055749","title":"Lexaria says oral GLP-1 drugs expand market as sector sales forecasts climb to USD 139 billion by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2644055749","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644055749?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:25","pubTimestamp":1781702729,"startTime":"0","endTime":"0","summary":"Lexaria’s GLP-1 industry update flagged accelerating demand for oral weight-loss drugs, citing 3 million Wegovy pill prescriptions filled since Jan. 5, 2026.The report highlighted market expansion beyond obesity, pointing to late-stage data showing up to 28.3% average weight loss with Lilly’s retatrutide.Sales forecasts were raised across the sector, including a TD Cowen 2030 GLP-1 estimate lifted to USD 139 billion from USD 101 billion.Safety remained the key product battleground, with gastrointestinal side effects cited as the main barrier to broader uptake.Lexaria positioned its DehydraTECH delivery approach as a potential mitigant, citing animal-study results showing 31% to 100% reductions in GI adverse events.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL8QJT5y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642938214","title":"Lexaria announces dosing completion in 2026 Animal Study 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2642938214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642938214?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:34","pubTimestamp":1781012045,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) announces that dosing has been completed in its 2026 Animal Study #2 evaluating a number of formulation enhancements with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-announces-dosing-completion-in-2026-animal-study-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-announces-dosing-completion-in-2026-animal-study-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642498447","title":"Lexaria completes dosing in animal study testing oral retatrutide, amycretin formulations","url":"https://stock-news.laohu8.com/highlight/detail?id=2642498447","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642498447?lang=en_us&edition=fundamental","pubTime":"2026-06-09 21:25","pubTimestamp":1781011521,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience completed dosing in its 2026 Animal Study #2 testing oral formulations of retatrutide and amycretin with its DehydraTECH platform.Results have not been presented; the study is collecting blood samples over 24 hours to assess absorption and tolerability.The work targets improved oral delivery of next-generation GLP-1 drugs, aiming to reduce gastrointestinal side effects while preserving effectiveness.The study also compares tablet versus capsule delivery to guide future product design and potential new intellectual property filings.Lexaria is funding the program internally, positioning the platform for potential partnering interest in late-stage obesity drug candidates.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL3C30HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640902092","title":"Lexaria Bioscience to attend BIO International Convention","url":"https://stock-news.laohu8.com/highlight/detail?id=2640902092","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640902092?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:25","pubTimestamp":1780493138,"startTime":"0","endTime":"0","summary":"Lexaria will attend the BIO International Convention in San Diego, California, on June 22-25.The meeting schedule is expected to be fully booked, reflecting elevated partnering interest in its DehydraTECH oral drug-delivery platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9YJMw9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636685452","title":"Lexaria Bioscience announces ethics approval for Human Pilot Study 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2636685452","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636685452?lang=en_us&edition=fundamental","pubTime":"2026-05-19 21:27","pubTimestamp":1779197227,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) announces that ethics approval has been received from an independent review board, for Human Pilot Study #7 that will eva...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-announces-ethics-approval-for-human-pilot-study-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-announces-ethics-approval-for-human-pilot-study-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636285160","title":"Lexaria wins ethics board clearance for oral semaglutide human pilot study #7","url":"https://stock-news.laohu8.com/highlight/detail?id=2636285160","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636285160?lang=en_us&edition=fundamental","pubTime":"2026-05-19 21:15","pubTimestamp":1779196528,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience received independent review board ethics clearance to launch Human Pilot Study #7 testing two oral DehydraTECH-semaglutide formulations against Novo Nordisk’s Wegovy tablets.The five-week, three-arm study will assess safety, tolerability, and pharmacokinetics under fasted dosing conditions, with dosing expected to start in mid-June.Results are aimed at supporting potential commercial partnerships tied to Lexaria’s oral GLP-1 delivery technology.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL2pm7XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633112852","title":"Lexaria CEO says pharma partner extends material transfer agreement through end-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633112852","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633112852?lang=en_us&edition=fundamental","pubTime":"2026-05-07 21:25","pubTimestamp":1778160321,"startTime":"0","endTime":"0","summary":"Lexaria management highlighted an extension of its Material Transfer Agreement with a global pharmaceutical partner through year-end 2026.CEO Rich Christopher told an investor interview the extension signals continued engagement around DehydraTECH, with additional data expected this year.Christopher outlined 2026 priorities focused on GLP-1 research, positioning results as a driver for partnering discussions.Business development activity was framed as part of a broader commercial strategy aimed at expanding partnering beyond GLP-1.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL72LBQS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633139047","title":"Lexar invests in IoT sensor-and-SaaS firm Munisense","url":"https://stock-news.laohu8.com/highlight/detail?id=2633139047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633139047?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:02","pubTimestamp":1778076173,"startTime":"0","endTime":"0","summary":"Lexar Partners BV took a stake in Munisense, an IoT business combining long-life sensors with a SaaS platform.Investment signals broader focus on tech-enabled services alongside SaaS, reflecting investor reassessment of service-layer models as AI lowers software build costs.Lexar cited high switching costs from Munisense’s data stream and 10-year sensor lifespan as key durability factors.Firm also highlighted deeper diligence on customer in-house build risk, alongside a portfolio value-creation framework and an AI-focused operating team to support scaling.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexar Partners BV published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL3mkhDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089985449.USD","BK4553","MUU","BK4141","LU0274383776.USD","IE0009356076.USD","LU2048586759.USD","LU2286300806.USD","BK4605","LU1316542783.SGD","LU1852331112.SGD","BK4543","BK4575","IE00B5949003.HKD","LU0109392836.USD","LU0203347892.USD","LU2360106780.USD","BK4532","LU1366333091.USD","LU2250418816.HKD","IE00B19Z3B42.SGD","LU2931357623.SGD","BK4566","LU0792757196.USD","BK4527","LU2458330243.SGD","BK4579","LU0889566641.SGD","MULL","BK4585","LU0203345920.USD","LU1267930813.SGD","BK4533","LU1323610961.USD","IE0002270589.USD","LU0719512351.SGD","LU2458330169.SGD","IE00B7SZLL34.SGD","BK4588","LU0056508442.USD","LEXX","LU0642271901.SGD","LU0157215616.USD","BK4512","LU0082616367.USD","LU0081259029.USD","MUD","LU2543165471.USD","LU2211815571.USD","LU1803068979.SGD","LU0889565833.HKD","LU2054465674.USD","GB00BDT5M118.USD","LU0127658192.USD","IE00B19Z3581.USD","LU0154236417.USD","BK4554"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945347","title":"Lexaria seeks ethics approval for five-week oral semaglutide study versus Wegovy tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945347","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633945347?lang=en_us&edition=fundamental","pubTime":"2026-05-05 21:10","pubTimestamp":1777986633,"startTime":"0","endTime":"0","summary":"Lexaria entered submissions seeking ethics clearance for Human Pilot Study #7, a five-week trial comparing two oral DehydraTECH-semaglutide formulations with Novo Nordisk’s oral Wegovy tablets.Results have not been presented; dosing is targeted to start in mid-June once quality-control testing and packaging are completed, with pre-dosing tasks expected to wrap by early June.Trial aims to assess safety, tolerability, and drug exposure over multiple weeks, focusing on whether DehydraTECH formulations can match or outperform commercial oral semaglutide while maintaining favorable tolerability.Study introduces a DehydraTECH semaglutide tablet format for first time, alongside a capsule, both using SNAC to support absorption in a longer-duration dosing regimen.Readout is positioned as a potential catalyst for commercial partnering interest tied to Lexaria’s oral drug delivery platform.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL1DcdJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632961760","title":"Lexaria CEO discusses DehydraTECH, GLP-1 strategy in new investor video series interview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632961760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632961760?lang=en_us&edition=fundamental","pubTime":"2026-05-01 21:27","pubTimestamp":1777642078,"startTime":"0","endTime":"0","summary":"Lexaria launched an ongoing investor video series, “Reformulated: Into the Mainstream,” featuring management interviews on strategy, pipeline, and market conditions.In inaugural episode, CEO Rich Christopher discussed DehydraTECH positioning in GLP-1 therapies.Christopher cited GLP-1 market worldwide revenue of about $75 billion in 2025.Management highlighted completion of five human GLP-1 studies spanning semaglutide, tirzepatide, and liraglutide.Lexaria outlined a multi-pronged commercial strategy, including outlicensing work under an active Material Transfer Agreement with a global pharmaceutical company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL4PPBtL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631124465","title":"Lexaria extends PharmaCO transfer agreement through Dec. 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2631124465","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631124465?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:17","pubTimestamp":1777468663,"startTime":"0","endTime":"0","summary":"Lexaria extended material transfer agreement with PharmaCO through Dec. 31, 2026 for preclinical evaluation of DehydraTECH in GLP-1 programs.Extension keeps temporary exclusive license in effect while PharmaCO reviews Lexaria 2026 R&D results.Parties plan additional strategic discussions with PharmaCO clinical and business development teams as data from ongoing studies is delivered in Q3 and Q4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDLbJL8jC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631178585","title":"Lexaria Bioscience extends material transfer agreement with pharma company","url":"https://stock-news.laohu8.com/highlight/detail?id=2631178585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631178585?lang=en_us&edition=fundamental","pubTime":"2026-04-29 21:16","pubTimestamp":1777468584,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) provided this update on the Material Transfer Agreement originally entered into on August 30, 2024 with a pharmaceutical ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-extends-material-transfer-agreement-with-pharma-company-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-extends-material-transfer-agreement-with-pharma-company-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629832152","title":"Lexaria signs CRO contracts for GLP-1 animal study #2","url":"https://stock-news.laohu8.com/highlight/detail?id=2629832152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629832152?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:09","pubTimestamp":1776949763,"startTime":"0","endTime":"0","summary":"Lexaria signed contracts with a contract research organization to run its 2026 Animal Study #2  on next-generation GLP-1 drug formulations.Study will test amycretin and retatrutide for compatibility with DehydraTECH, focusing on pharmacokinetics and tolerability.Program will be funded from existing corporate resources.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDLc2JGYn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629347930","title":"Lexaria sees oral GLP-1 pill market reaching $17 billion-$60 billion by mid-2030s","url":"https://stock-news.laohu8.com/highlight/detail?id=2629347930","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629347930?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:10","pubTimestamp":1776777024,"startTime":"0","endTime":"0","summary":"Lexaria projected oral GLP-1 weight-loss pills could generate USD 17 billion to USD 60 billion in annual sales by mid-2030s, based on industry forecasts for total GLP-1 market size.Novo Nordisk disclosed more than 600,000 prescriptions for Wegovy pill were written in first two months following January 2026 US launch.GlobalData forecast 51% of Wegovy revenue growth from 2026-2031 to come from pill format, with franchise expected to reach USD 15.9 billion in annual revenue by 2030.Novo Nordisk executive estimate cited oral GLP-1 drugs could reach 33% of broader GLP-1 market within a few years of launch.Lexaria positioned DehydraTECH as an oral-delivery enhancer for semaglutide, tirzepatide, liraglutide, with 2026 R&D plans to assess next-generation GLP-1 candidates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL52bW63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627280640","title":"Lexaria Bioscience engages CRO for 2026 GLP-1-A26-1 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2627280640","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627280640?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:24","pubTimestamp":1776259450,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience (LEXX) announced the engagement of the contract research organization to execute and report on its 2026 animal Study #1 that wil...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-engages-cro-for-2026-glp-1-a26-1-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lexaria-bioscience-engages-cro-for-2026-glp-1-a26-1-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LEXX","BK4144","BK4590","BK4007","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627651287","title":"Lexaria signs CRO contracts for GLP-1 animal study execution and reporting","url":"https://stock-news.laohu8.com/highlight/detail?id=2627651287","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627651287?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:13","pubTimestamp":1776258788,"startTime":"0","endTime":"0","summary":"Lexaria signed contracts with a contract research organization to run Animal Study GLP-1-A26-1 focused on DehydraTECH-semaglutide and DehydraTECH-CBD formulations.Materials sourcing began, with dosing targeted to start within about 60 days.Study aims to support new patent claims, including testing alternatives to SNAC used in Novo Nordisk oral GLP-1 tablets.Lexaria expects pharmacokinetic sampling over an 8-24-hour post-dose window, including measurement of drug levels in brain tissue.Program will be funded from existing corporate resources.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief on April 15, 2026, and is solely responsible for the informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL3sR5fZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627450815","title":"Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2627450815","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627450815?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:35","pubTimestamp":1776101751,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corp reports results for the quarter ended February 28 - Earnings SummaryLexaria Bioscience Corp LEXX.OQ reported a quarterly adjusted loss of 6 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nL8N40W1WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627457999","title":"Lexaria FY26 Q2 net loss narrows 43.8% to US$ 3 million; revenue drops to US$ 20,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2627457999","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627457999?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:08","pubTimestamp":1776100100,"startTime":"0","endTime":"0","summary":"Lexaria posted a net loss of US$ 3 million for the six months ended Feb. 28, 2026, narrowing from US$ 5.4 million a year earlier.Revenue slid 94.4% to US$ 20,000 on lower license fees following expiration of Premier Anti-Aging licensing contract.Research and development expense fell 68.5% to US$ 1.1 million after completion of Phase 1b clinical trial GLP-1-H24-4 in December 2025.Cash and cash equivalents totaled about US$ 5.1 million, with net working capital of US$ 5.6 million at Feb. 28, 2026.Management expects current cash resources to fund operations through first quarter of fiscal 2027, while noting substantial doubt about ability to continue as going concern within one year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDLbyCt24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LEXX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626194385","title":"Lexaria Bioscience Corp  expected to post a loss of 9 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2626194385","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626194385?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:04","pubTimestamp":1775819060,"startTime":"0","endTime":"0","summary":"Lexaria Bioscience Corp  expected to post a loss of9cents a share - Earnings Preview Lexaria Bioscience Corp LEXX.OQ LEXX.O is expected to  show a fall in quarterly revenue when it reports  results on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nL8N40T0PX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LEXX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":52,"code":"91000000","status":"200"}]}}